It mainly includes: (i) cancer vaccines, such as sipuleucel-T using for prostate cancer (22); (ii) cytokine therapies, such as INF (23), interleukin-2 (IL-2) (24); (iii) Oncolytic virus therapies, such as T-VEC (25); and (iv) chimeric antigen receptor T-cell (CAR-T) and adoptive cell transfer (ACT) (26); (v) antibody therapies or immune checkpoint inhibitors (ICI) such as rituximab and Trastuzumab, as well as CTLA-4 and PD-1 (27, 28). This evidence concerns the gene IL2 and Familial prostate cancer.